We test new medical agents in vitro on primary cells and cell lines for their compatibility and un desirable side effects. Our customized and reliable testing strategies for toxicity analysis support pharmaceutical companies in the early stages of product development
CELLphenomics delivers innovative PD3D® models to oncology drug development, accelerating your journey from the laboratory bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives.
PD3D® culture models have been shown to reliably recapitulate the architecture of the donor tissue.
In the past, 3D organoid models have shown their relevance in the pre-clinical setting. Beside the preservation of tissue architecture, their main benefit over mouse models is the preservation of the genomic background from the donor tissue.
We have developed protocols that allow for semi-automated screening of PD3D® models.
5. Clinical and -omics data
For most of our models basic clinical data of the donor tumor are available. Together with data from exome- and RNA-sequencing our models are the foundation of your research projects.